Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.34 |
| ▸ | F2 | P00734 | 7/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485866 | 0.92 | ITGB3 (0.33) | ITGB3ITGA2BF2F10PLG | |
| SCHEMBL6476916 | 0.92 | OPRM1 (0.31) | TMPRSS15OPRK1OPRM1 | |
| SCHEMBL6482270 | 0.92 | ITGB3 (0.35) | ITGB3ITGA2BF2F10PLG | |
| SCHEMBL6487745 | 0.92 | ITGB3 (0.36) | ITGB3ITGA2BF2F10PLG | |
| Hydrochloric Acid SCHEMBL6485317 | 0.90 | ITGB3 (0.38) | ITGB3ITGA2BF2F10PLG | |
| SCHEMBL6475692 | 0.88 | ITGB3 (0.36) | ITGB3ITGA2BF2TMPRSS15F10 | |
| Acetic Acid SCHEMBL6488369 | 0.88 | F2 (0.35) | ITGB3ITGA2BF2F10PLG | |
| SCHEMBL6482023 | 0.86 | FAP (0.30) | OPRK1OPRM1 | |
| Hydrochloric Acid SCHEMBL6489976 | 0.85 | ITGB3 (0.36) | ITGB3ITGA2BF2F10PLG | |
| SCHEMBL6484519 | 0.85 | ITGB3 (0.36) | ITGB3ITGA2BF2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | ITGB3 4797/4885ITGA2B 4820/4885F2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.